A breath test can successfully pick up lung cancer with "moderate accuracy" even in the early stages, reveals research published ahead of print in Thorax.
It could revolutionise the way cancer is detected and potentially save lives, say the authors.
The test comprises a chemical colour sensor, which detects tiny changes in the unique chemical signature of the breath of people with lung cancer.
Metabolic changes in lung cancer cells cause changes in the production and processing of volatile organic compounds, which are then breathed out
The researchers used the colour sensor to test the breath of 122 people with different types of respiratory disease, and 21 healthy people.
Included in the group with respiratory illness were 49 people with small cell lung cancer at various stages of development.
The research team used the sensor results from 70% of the study participants to develop a predictive model, the accuracy of which was then tested on the remaining 30%.
The results showed that the test was able to accurately predict the presence of cancer in just under three out of four of those with lung cancer.
The results were not affected by age, gender, or stage of disease.
Other approaches to breath testing have been used, say the authors. This includes gas chromatography and mass spectrometry, which requires a great deal of expertise to use and is very expensive.
As cancer is often silent in its early stages and symptoms are often not specific, it is often difficult to pick up the disease at a stage when it could be treated effectively, say the authors.
Diagnosis is often therefore only made when the disease is advanced.
"Ultimately, this line of investigation could lead to an inexpensive, non-invasive screening or diagnostic test for lung cancer," they conclude.
Source: BMJ Specialty Journals
Related stories:
Gene that causes childhood cancer neuroblastoma is found
Scientists have discovered gene mutations that are the main cause of the inherited version of the childhood cancer neuroblastoma. In addition, the researchers found that the same mutations play a significant role in high-risk forms of non-inherited neuroblastoma, the more common form of the disease.
Gene panel predicts lung cancer survival, study finds
Researchers from four leading cancer centers have confirmed that an analysis involving a panel of genes can be used to predict which lung cancer patients will have the worst survival. The finding could one day lead to a test that would help determine who needs more aggressive treatment. The study, the largest of its kind, appears online in
Nature Medicine.
Faulty DNA repair could be a risk factor for lung cancer in nonsmokers
People who have never smoked but whose cells cannot efficiently repair environmental insults to DNA are at higher risk of developing lung cancer than those with effective genomic repair capability, according to researchers from the Department of Epidemiology at The University of Texas M. D. Anderson Cancer Center.
Patient's own infection-fighting T cells put late-stage melanoma into long-term remission
Case is first to show safety and effectiveness of using cloned cells alone to kill tumors
Researchers describe the first successful use of a human patient's cloned infection-fighting T cells as the sole therapy to put an advanced solid-tumor cancer into long-term remission. A team led by Cassian Yee, M.D., an associate member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, reports these findings in the June 19 issue of the
New England Journal of Medicine.
CT lung cancer screening no cure-all for smokers
Screening for lung cancer with computed tomography (CT) may help reduce lung cancer deaths in current and former smokers, but it won't protect them from other causes of death associated with smoking, according to a new study published in the July issue of the journal
Radiology.
Team find gene signature profile for metastasis
A common signature of tiny, specific pieces of non-coding genetic material known as microRNAs (miRNAs) may be directly involved in the spread of cancer to other parts of the body. Researchers at the Kimmel Cancer Center at Jefferson in Philadelphia and Ohio State University Medical Center in Columbus have identified such a signature, made up mostly of overexpressed miRNAs. The findings, reported at the annual meeting of the American Society of Clinical Oncology in Chicago, may represent a novel diagnostic tool in characterizing gene targets in metastatic cancer.
Medics solve an ancient riddle -- and offer new tool for diagnosis
A puzzling medical condition, identified more than 2,000 years ago by Hippocrates, has finally been explained by researchers at the University of Leeds.
Researchers find common gene disorder doubles risk of lung cancer, even among nonsmokers
Mayo Clinic researchers have found that carrying a common genetic disorder doubles the risk of developing lung cancer in smokers and nonsmokers. The study is published in the May 26 issue of the
Archives of Internal Medicine, a journal published by the American Medical Association.